The stock has a 36-month beta value of -0.37. Opinions on the stock are mixed, with 6 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VOR is 59.84M, and at present, short sellers hold a 2.59% of that float. On December 06, 2024, the average trading volume of VOR was 925.17K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
VOR) stock’s latest price update
The stock price of Vor Biopharma Inc (NASDAQ: VOR) has plunged by -0.30 when compared to previous closing price of 0.85, but the company has seen a 1.25% gain in its stock price over the last five trading sessions. https://thefly.com reported 2024-11-08 that Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Vor Bio to $8 from $10 and keeps an Outperform rating on the shares following the Q3 report. The firm cites updated spending estimates based on guidance from management for the target. It acknowledges Vor’s “financial overhang,” but still views the company as a “deeply discounted innovator in the biotech sector.”
VOR’s Market Performance
Vor Biopharma Inc (VOR) has experienced a 1.25% rise in stock performance for the past week, with a -2.03% drop in the past month, and a -22.71% drop in the past quarter. The volatility ratio for the week is 8.52%, and the volatility levels for the past 30 days are at 9.15% for VOR. The simple moving average for the last 20 days is -2.05% for VOR stock, with a simple moving average of -32.44% for the last 200 days.
Analysts’ Opinion of VOR
Many brokerage firms have already submitted their reports for VOR stocks, with Wedbush repeating the rating for VOR by listing it as a “Outperform.” The predicted price for VOR in the upcoming period, according to Wedbush is $18 based on the research report published on July 26, 2022 of the previous year 2022.
Goldman, on the other hand, stated in their research note that they expect to see VOR reach a price target of $6. The rating they have provided for VOR stocks is “Neutral” according to the report published on April 27th, 2022.
H.C. Wainwright gave a rating of “Buy” to VOR, setting the target price at $26 in the report published on December 17th of the previous year.
VOR Trading at 8.92% from the 50-Day Moving Average
After a stumble in the market that brought VOR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.17% of loss for the given period.
Volatility was left at 9.15%, however, over the last 30 days, the volatility rate increased by 8.52%, as shares surge +0.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.29% upper at present.
During the last 5 trading sessions, VOR rose by +0.95%, which changed the moving average for the period of 200-days by -57.58% in comparison to the 20-day moving average, which settled at $0.8600. In addition, Vor Biopharma Inc saw -62.56% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VOR starting from Attar Eyal C., who sale 14,645 shares at the price of $1.39 back on Jun 03 ’24. After this action, Attar Eyal C. now owns 96,063 shares of Vor Biopharma Inc, valued at $20,357 using the latest closing price.
Stock Fundamentals for VOR
Current profitability levels for the company are sitting at:
- -9.65 for the present operating margin
- 0.78 for the gross margin
The net margin for Vor Biopharma Inc stands at -9.2. The total capital return value is set at -1.16. Equity return is now at value -90.79, with -66.35 for asset returns.
Currently, EBITDA for the company is -114.37 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 3.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.69.
Conclusion
To sum up, Vor Biopharma Inc (VOR) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
